Sign in
Taking peopleNo phase

Real-world use of the EkoSonic system for sudden lung blood clots in China

Collects everyday care results of the EkoSonic device in Chinese adults with acute pulmonary embolism.

Key facts

Who runs it
Boston Scientific Corporation
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism
Status
Recruiting
People taking part
30 people, planned
Started
30 Sept 2026
Expected to end
30 May 2029
Type of study
Observational
Treatments tested
  • EkoSonicTM Endovascular System
Record updated
26 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in China with a sudden blood clot in the lungs (acute pulmonary embolism) whose doctor chose treatment with the EkoSonicTM Endovascular System and r-tPA. It collects real-world results from routine care.

Age
18 Years and older
Sex
All sexes can join
Disease stage
Acute pulmonary embolism with symptoms that started less than 14 days ago. On a heart ultrasound, the right lower heart chamber must be as wide as or wider than the left one (ratio ≥1).
Earlier treatment
The doctor must have already chosen to treat the patient with the EkoSonicTM Endovascular System with r-tPA.
Biomarker or test result
Heart ultrasound (echocardiography) showing a right-to-left ventricle size ratio of ≥1.

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • The patients with acute symptomatic pulmonary embolism (Symptomatic duration < 14 days)
  • The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image
  • Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient

Who cannot take part

  • The patients with acute symptomatic pulmonary embolism (Symptomatic duration < 14 days)
  • The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image
  • Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study to collect the real-world clinical outcome data of EkoSonicTM Endovascular System in Chinese patients with acute pulmonary embolism during practical clinical care.

The group in the trial

  • Single group observational study

    To collect the real-world clinical outcome data of EkoSonicTM Endovascular System in Chinese patients with acute pulmonary embolism during practical clinical care.

    Treatment: EkoSonicTM Endovascular System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
EkoSonic Endovascular System in China RWS(ANTEATER)
Plain-language title
Real-world use of the EkoSonic system for sudden lung blood clots in ChinaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
26 October 2026